Skip to content

MiMedx Group MDXG Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

IAR
Integra LifeSciencesIART
Artivion logo
ArtivionAORT
Solventum logo
SolventumSOLV
Vericel logo
VericelVCEL
Enovis logo
EnovisENOV
CorMedix logo
CorMedixCRMD

Other financials

Income statement

See full
Revenue$59.0M-33.1%
Gross profit$41.6M-41.9%
Operating income-$16.0M-295%
Net income-$10.9M-255%
EPS (diluted)-$0.07-240%

Balance sheet

See full
Cash & equivalents$159.8M+50.1%
Total debt$17.6M-5.7%
Total equity$242.9M+19.8%
Total assets$308.7M+14.1%

Cash flow

See full
Operating cash flow$1.9M-64.5%
CapEx$570.0K+51.2%
Free cash flow$1.3M-73.4%

Valuation

See full
Market cap$567.48M-33.9%
Enterprise value$425.3M-44.8%
P/E18.5×-2.9×
P/S1.5×-1.0×

Profitability

See full
Gross margin81%-0.9pp
Operating margin10.2%-5.1pp
Net margin7.9%-3.5pp
FCF margin17.8%-0.5pp

Returns & leverage

See full
Return on equity13.8%-8.6pp
Debt / equity0.1×0.0×
Current ratio5.4×+0.7×

Where this comes from

Reported directly by MiMedx Group in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: MiMedx Group’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiMedx Group's common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MiMedx Group's common stock, shares authorized (in shares)?
MiMedx Group (MDXG) reported common stock, shares authorized (in shares) of $250M in Q1 2026.
How has MiMedx Group's common stock, shares authorized (in shares) changed year-over-year?
MiMedx Group's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $250M to $250M.
What is the long-term trend for MiMedx Group's common stock, shares authorized (in shares)?
Over 4 years (2021 to 2025), MiMedx Group's common stock, shares authorized (in shares) has grown at a 7.5% compound annual growth rate (CAGR), from $187.5M to $250M.